The initiation of coverage by a major financial institution like B of A Securities with a Buy rating and a high price target usually leads to increased investor interest and potentially a rise in the stock price in the short term. The specific mention of Apogee Therapeutics and the optimistic price target of $80 highlight a strong positive sentiment towards the company's stock, suggesting a bullish outlook.